Liabooks Home|PRISM News
PRISM

#Wegovy

Total 5 articles

Novo Nordisk Wegovy package on a China map with a downward price arrow
EconomyEN
Novo Nordisk Wegovy China Price Cut: A Tactical Move for Market Dominance

Novo Nordisk slashes Wegovy prices in China to fight off competition from Eli Lilly and local firms. Discover the impact on the $20B Chinese obesity market.

Novo Nordisk Soars 8% as U.S. Greenlights Oral Wegovy, Unlocking Massive New Market
EconomyEN
Novo Nordisk Soars 8% as U.S. Greenlights Oral Wegovy, Unlocking Massive New Market

Novo Nordisk (NVO) stock jumped 8% following FDA approval for the oral pill version of its weight-loss drug Wegovy. The move is expected to significantly broaden patient access and intensify competition with Eli Lilly.

FDA Approves First-Ever Pill Version of Blockbuster Weight-Loss Drug Wegovy
TechEN
FDA Approves First-Ever Pill Version of Blockbuster Weight-Loss Drug Wegovy

The US FDA has approved the first-ever pill form of Novo Nordisk's blockbuster weight-loss drug, Wegovy. Showing comparable results to the injection in trials, the daily pill is set to launch in January 2026.

FDA Approves Wegovy Pill, Igniting New Front in Billion-Dollar Weight-Loss Drug Race
TechEN
FDA Approves Wegovy Pill, Igniting New Front in Billion-Dollar Weight-Loss Drug Race

The FDA has approved a once-daily pill version of Novo Nordisk's blockbuster weight-loss drug Wegovy, offering a new option versus the weekly shot and escalating competition with Eli Lilly.

Pung Ja's Wegovy Rejection: How One K-Celeb's Diet Signals a Tipping Point for the $100B Wellness Industry
K-CultureEN
Pung Ja's Wegovy Rejection: How One K-Celeb's Diet Signals a Tipping Point for the $100B Wellness Industry

Korean star Pung Ja's recent weight loss is more than a glow-up. Her rejection of Wegovy for lifestyle changes signals a major shift in the wellness market.